CG Oncology, Inc.
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for bladder cancer. Its lead program is designed to both directly kill cancer cells and stimulate an anti-tumor immune response, with the initial focus on high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC). The company is still in development mode and does not yet sell an approved product, so its value proposition is tied primarily to clinical success, regulatory approval, and eventual commercialization. In addition to its core drug program, CG Oncology has built in-house chemistry, manufacturing and controls capabilities and commercial-readiness infrastructure to support a potential launch. The company also has a commercial and development revenue stream through Biovire, a contract manufacturing business focused on fill-and-finish services for novel drugs and medical devices.
Fiscal year 2025 · change from previous year
Development 2023–2025
Business
Share of revenueDevelopment of cretostimogene grenadenorepvec as a potential therapy for bladder cancer, especially NMIBC.
Preclinical and clinical trial activities supporting the advancement of the lead program.
Internal process development, analytical development, and virus-related manufacturing support.
Revenue recognized from licensing and collaboration agreements while the product remains in development.
Biovire fill-and-finish services for novel drugs and medical devices.
Products
Reported · share of revenue- Commercial and Development Revenue80.0 %
- License and Collaboration Revenue20.0 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
CG Oncology’s primary end customers are patients with high-risk and intermediate-risk NMIBC, but the company’s near-term economic counterparties are pharmaceutical collaborators, license partners, and healthcare providers involved in clinical trials. If cretostimogene is approved, the commercial customer base would expand to urologists, oncology centers, and hospitals treating bladder cancer patients. In the meantime, the company also serves biopharma customers through Biovire’s fill-and-finish manufacturing services for novel drugs and medical devices. The company’s collaboration revenue depends on partners that value access to its technology, intellectual property, and development capabilities. Demand in the eventual commercial market will be driven by clinical efficacy, tolerability, convenience, and the ability to compete against BCG and other NMIBC therapies.
Patients with high-risk or intermediate-risk NMIBC are the intended therapeutic population for cretostimogene because they need effective bladder-sparing treatment options.
Hospitals, clinics, and physicians would administer the therapy and determine adoption based on safety, efficacy, and convenience.
Partners license or collaborate on the platform to gain access to the drug candidate, development know-how, or commercialization rights.
Customers of Biovire buy fill-and-finish services for novel drugs and medical devices, creating non-product revenue.
These stakeholders support enrollment and execution of clinical studies needed to generate regulatory evidence.
Strategy
CG Oncology’s strategy is to advance cretostimogene through late-stage development and position it as a backbone therapy in bladder cancer, starting with NMIBC. The company is also building commercial infrastructure ahead of a potential FDA approval, which is important because it has no prior product-launch experience. A second strategic pillar is maintaining strong CMC and manufacturing capabilities so it can support clinical supply and future commercialization without relying entirely on third parties. The company also expects to fund operations through existing cash, future equity or debt, and collaboration/licensing arrangements until product revenue is possible. Biovire adds a complementary revenue stream and manufacturing capability that can support both operations and strategic flexibility.
The company depends on a single lead asset, so clinical success is the main driver of future value and commercialization potential.
The company has no commercial product history, so building sales, marketing, and market access capabilities is necessary to convert approval into revenue.
Until product sales begin, the company must rely on capital markets and collaboration income to fund operations.
Reliable clinical and future commercial supply is critical for a biologic/oncolytic therapy and can be a differentiator in regulatory review and launch readiness.
Geography
CG Oncology is headquartered in the United States and its business is currently centered on U.S.-based clinical development, regulatory engagement, and commercial preparation. The company’s lead indication, NMIBC, is a U.S. and global oncology market, but the filings emphasize U.S. patient estimates and U.S.-centric development activities. The company also notes exposure to foreign jurisdictions through regulation, litigation, supply chain, and potential future commercialization, even though no country-level revenue disclosure is provided. Because the company is still pre-commercial for its lead drug, geography matters more through trial execution, regulatory pathways, and manufacturing/supply-chain resilience than through current sales mix. Biovire and future collaboration activity could broaden the operating footprint over time, but the disclosed revenue base is not broken out by country.
Risks
CG Oncology is highly exposed to clinical, regulatory, and commercialization risk because it depends entirely on cretostimogene, its only product candidate. If the program fails, is delayed, or does not achieve approval, the company may never generate product revenue and could need to raise capital on unfavorable terms. The competitive environment is intense, with BCG and multiple larger pharmaceutical and biotechnology companies pursuing NMIBC therapies that may be safer, more effective, or faster to market. As a development-stage biopharma company, it also faces manufacturing, trial execution, intellectual property, and reimbursement risk, all of which can materially affect adoption even if approval is obtained. Broader risks include litigation, government investigations, supply-chain disruption, pandemics, and macroeconomic or tariff-related pressure that can raise costs and slow clinical operations.
- Dependence on a single product candidateImpact: CriticalLikelihood: High
The company currently depends entirely on cretostimogene, so any setback in development or approval would materially harm the business.
Exposure: All corporate value is concentrated in one program.
- Clinical and regulatory failureImpact: CriticalLikelihood: High
The company has no approved products, so it cannot generate product revenue unless trials succeed and regulators approve the therapy.
Exposure: Late-stage NMIBC development and FDA review.
- Manufacturing and supply-chain riskImpact: HighLikelihood: High
Clinical and future commercial supply depends on complex biologic manufacturing and third-party logistics that can be disrupted.
Exposure - Competitive pressure in NMIBCImpact: HighLikelihood: Medium
Established and emerging competitors may reach market first or offer better efficacy, safety, or convenience than cretostimogene.
Exposure: BCG-naïve and BCG-exposed bladder cancer patients.
- Financing riskImpact: HighLikelihood: Medium
The company expects to need substantial additional funding before product sales are possible, and capital may not be available on favorable terms.
Exposure - Litigation and regulatory enforcementImpact: MediumLikelihood: Low
Operating in a highly regulated industry creates exposure to IP, product liability, privacy, anti-kickback, and other claims.
Exposure: U.S. and foreign jurisdictions.
Accounting
Judgemental itemsRevenue is currently driven by collaboration agreements rather than product sales, so contract terms and performance obligations determine timing and amount recognized.
Impact: Can create uneven revenue recognition across periods.
Clinical trial, CRO, and manufacturing costs are estimated and accrued, so management judgment affects quarterly expenses and liabilities.
Impact: Can materially change reported operating loss in a quarter.
The company invests cash in short-term securities, requiring classification and valuation judgments that affect reported assets and other income.
Impact: Affects balance sheet liquidity presentation and non-operating results.
As a development-stage biotech, equity awards are a meaningful part of compensation and can significantly affect G&A and R&D expense.
Impact: Can distort comparability across periods if grant activity changes.
Similar listed companies
Publicly listed companies with a comparable business focus.
Crescent Biopharma, Inc
CBIO · Pharmaceutical Preparations
GENELUX Corp
GNLX · Pharmaceutical Preparations
GENELUX Corp is a U.S.-based clinical-stage biopharmaceutical company focused on developing oncolytic vaccinia virus immunotherapies, led by its Olvi-Vec program.
Candel Therapeutics, Inc.
CADL · Biological Products, (No Diagnostic Substances)
enGene Therapeutics Inc.
ENGN · Biological Products, (No Diagnostic Substances)
Crispr Therapeutics AG
CRSP · Biological Products, (No Diagnostic Substances)
CRISPR Therapeutics AG is a gene-editing biopharmaceutical company built around CRISPR/Cas9 technology and the development of gene-based medicines for serious diseases.
GT Biopharma, Inc.
GTBP · Pharmaceutical Preparations
Last updated: 24/09/2026